Expertise in
9
conditions

Karim Boudjema

CHU Rennes
Rennes, FR 
Expertise in
9
conditions
CHU Rennes
Rennes, FR 

Overview

Karim Boudjema practices practicing medicine in Rennes, France.

Mr. Boudjema is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Liver Failure, Liver Transplant, and Hepatectomy.

He is actively involved in clinical research, co-authoring 218 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

CHU Rennes
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma: Multicenter Randomized Double-blind Placebo Controlled Trial (SOMAPROTECT01)
Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma: Multicenter Randomized Double-blind Placebo Controlled Trial (SOMAPROTECT01)
Enrollment Status: Completed
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drug: Somatostatin Infusion
Study Phase: Phase 3
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
Impact of Donor and Recipient CYP3A5 Genetic Polymorphism on Tacrolimus Exposure in Patients With Hepatic Transplant
Impact of Donor and Recipient CYP3A5 Genetic Polymorphism on Tacrolimus Exposure in Patients With Hepatic Transplant
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Other
Study Phase: Not Applicable
De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study
De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study
Enrollment Status: Withdrawn
Publish Date: December 14, 2022
Intervention Type: Drug
Study Phase: Phase 3
Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection
Prospective Randomized Study Comparing the Morbidity and Mortality After Liver Resection for Synchronous Colorectal Cancer Metastases When Performed Either During or 12 to 14 Weeks After the Primary Resection
Enrollment Status: Terminated
Publish Date: March 11, 2019
Intervention Type: Procedure
Study Phase: Not Applicable
Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation
Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation
Enrollment Status: Completed
Publish Date: January 28, 2019
Intervention Type: Other
View 5 Less Clinical Trials

217 Total Publications

Guidelines 2025: perioperative management of adult patients undergoing liver resection.
Guidelines 2025: perioperative management of adult patients undergoing liver resection.
Journal: Anaesthesia, critical care & pain medicine
Published: May 27, 2026

Frequently Asked Questions about Karim Boudjema

Is Karim Boudjema a top-rated expert for Liver Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Karim Boudjema is classified as an Elite expert for Liver Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karim Boudjema participate in research or clinical trials?

Yes. Karim Boudjema has published 217 articles and abstracts on conditions like Liver Transplant. You can view a list of Karim Boudjema's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Boudjema's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile